Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Changes in Oxygen Saturation and the Retinal Nerve Fibre Layer in Patients with Optic Neuritis during a Six-Month Follow-up
Multiple Sclerosis
P15 - Poster Session 15 (12:00 PM-1:00 PM)
9-014

The aim of the study was to assess changes in the retinal nerve fibre layer (RNFL) and in retinal oxygen saturation [arterial (AS), venous (VS) and arterio-venous (A-V) difference] in the affected and unaffected eye during a six-month follow-up in patients with history of recent optic neuritis (ON).

Previous cross-sectional studies reported alterations of retinal oxygen saturation in ON, but there has been no longitudinal evaluation of the retinal saturation changes in ON.

Fifty patients with ON due to multiple sclerosis (MS) within 3 months of onset of symptoms were enrolled (17 males, mean age 35.3). All patients were examined at baseline (V1) and after 6 months (V2) using optical coherence tomography (OCT) to get retinal nerve fibre layer (RNFL) values, and automatic retinal oximetry to obtain saturation values.

At V1, AS was significantly increased in affected eye compared to unaffected eye (99.5% vs. 98%, p = 0.03). Significant decrease in A-V difference from baseline was detected in both eyes (for ON eye: 32% vs. 29%, p = 0.004; for fellow eye: 31.4% vs. 30%, p = 0.04). At V1, there were no significant differences in RNFL, significant loss of RNFL was confirmed in the affected eye at V2 (95 μm vs. 86 μm, p = 0.0002) and in comparison to the fellow eye (86 μm vs. 94 μm, p = 0.0002).

Retinal oximetry is altered in both eyes in MS patients with unilateral ON. During the course of the disease, the retinal oxygen consumption decreases to a different degree in each eye and this change is not completely followed by changes in the RNFL thickness, suggesting either sub-clinical ON or systemic effects in the clinically unaffected eye.

Authors/Disclosures
Petr Hlustik, MD, PhD (Palacký University Olomouc)
PRESENTER
The institution of Prof. Hlustik has received research support from Czech Health Research Council (AZV CR).
Pavel Hok, MD (University Hospital Olomouc) Dr. Hok has nothing to disclose.
Tereza Svrcinova Tereza Svrcinova has nothing to disclose.
No disclosure on file
No disclosure on file
Michal Kral No disclosure on file
No disclosure on file
Jan Mares, MD Dr. Mares has nothing to disclose.
Petr Kanovsky, PhD Dr. Kanovsky has nothing to disclose.
No disclosure on file